Inotiv, Inc. (NOTV)

5.42 -0.20 (-3.56%) At close: 04:00PM EDT

Inotiv, Inc.

2701 Kent Avenue
West Lafayette, IN 47906
United States
765 463 4527
https://www.inotivco.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 1,955

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Robert W. Leasure Jr.	President, CEO & Director	2M	N/A	1960
Ms. Beth A. Taylor CPA	Senior VP of Finance & CFO	461.16k	N/A	1965
Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D.	Chief Strategy Officer & Director	438.61k	N/A	1966
Dr. Peter T. Kissinger	Founder, Chairman Emeritus & Scientific Advisor	330.12k	N/A	1945
Mr. Brennan Freeman	VP of Finance, Principal Accounting Officer & Corporate Controller	N/A	N/A	1987
Ms. Andrea Castetter	Senior VP, General Counsel & Corporate Secretary	N/A	N/A	N/A
Dr. Adrian Hardy Ph.D.	Executive VP of Global Marketing & Corporate Development	2.74M	N/A	1971
Mr. Jeffrey Arthur Krupp	Chief Human Resources Officer	N/A	N/A	1971
Mr. John Gregory Beattie DSA	Chief Operating Officer of DSA	N/A	N/A	1967
Mr. Michael Garrett M.S.	Chief Commercial Officer	N/A	N/A	1968

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Corporate governance

Inotiv, Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.